Reihaneh Alsadat Mahmoudian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Reihaneh Alsadat Mahmoudian has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Mohammad Reza Abbaszadegan
Department of Medical Genetics and Molecular Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
4 shared publications - Moein Farshchian
Stem Cell and Regenerative Medicine Research Group, Academic Center for Education, Culture and Research (ACECR), Khorasan Razavi, Mashhad, Iran
3 shared publications Soodabeh Shahidsales
Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
2 shared publicationsAdele Azarshab
Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
1 shared publication- Ahmad Asoodeh
Department of Chemistry, Faculty of Science, Ferdowsi University of Mashhad, Mashhad, Iran
1 shared publication - Akram Hoseinzadeh
Department of Immunology, School of Medicine, Semnan University of Medical Sciences, Semnan, Iran
1 shared publication
Latest Publications
- Open Access
- 22 October 2026
- Published by Springer Nature in Experimental Hematology & Oncology
- Vol. 15 (1) , 108
Oncogenic RAS as an adaptive signaling ecosystem: context-dependent vulnerabilities and resistance-informed therapeutic design
Direct RAS targeting has progressed from pharmacologic proof of concept to routine treatment for selected KRAS G12C-mutant cancers. KRAS G12C inhibitors an
- 22 October 2026
- Published by Springer Nature in Experimental Hematology & Oncology
- Vol. 15 (1) , 108
Open AccessOncogenic RAS as an adaptive signaling ecosystem: context-dependent vulnerabilities and resistance-informed therapeutic design
Direct RAS targeting has progressed from pharmacologic proof of concept to routine treatment for selected KRAS G12C-mutant cancers. KRAS G12C inhibitors an
- Open Access
- 6 August 2026
- Published by Springer Nature in Egyptian Journal of Medical Human Genetics
- Vol. 27 (1) , 68
Context-dependent interactions between immune checkpoint and epithelial-mesenchymal transition programs shape the tumor microenvironment in esophageal squamous cell carcinoma
Background: Immune checkpoint (ICP) and epithelial-mesenchymal transition (EMT) pathways are key biological processes implicated in the progression of esophageal squamous cell carcinoma (ESCC). However, their transcriptional interplay and interactions with the tumor immune microenvironment remain incompletely characterized. Methods: Transcriptomic, somatic mutation, and clinical data from TCGA-ESCC (n = 95) were analyzed using a predefined hypothesis-driven gene panel comprising five ICP genes (PDCD1, CD274, CTLA-4, HAVCR2, LAG-3) and two EMT markers (TWIST1, MMP13). Immune cell infiltration was estimated using multiple computational deconvolution algorithms. Tumor mutational burden (TMB), ESTIMATE, and TIDE scores were assessed as exploratory immune-related metrics. Findings were validated in an independent microarray cohort (GSE53624). Results: ICP and EMT genes formed distinct yet partially overlapping expression modules. HAVCR2 demonstrated the strongest and most consistent association with EMT-related signatures across datasets. Elevated expression of most ICP genes and MMP13 was associated with poorer overall survival, whereas TWIST1 exhibited dataset-dependent prognostic behavior. ICP-high tumors were characterized by features of an immunologically active yet regulatory-enriched microenvironment, while EMT-related genes were linked to fibroblast- and stroma-dominant profiles. Advanced-stage tumors displayed concurrent immune activation and immune evasion signals. TMB was low overall and tended to decreased across stages, with no significant prognostic association. Conclusion: These findings delineate context-dependent transcriptional interactions between ICP and EMT pathways in ESCC and highlight the complexity of the tumor immune microenvironment beyond single-parameter biomarkers such as TMB. All associations are exploratory and hypothesis-generating, requiring mechanistic and prospective validation prior to translational application.
- 6 August 2026
- Published by Springer Nature in Egyptian Journal of Medical Human Genetics
- Vol. 27 (1) , 68
Open AccessContext-dependent interactions between immune checkpoint and epithelial-mesenchymal transition programs shape the tumor microenvironment in esophageal squamous cell carcinoma
Background: Immune checkpoint (ICP) and epithelial-mesenchymal transition (EMT) pathways are key biological processes implicated in the progression of esophageal squamous cell carcinoma (ESCC). However, their transcriptional interplay and interactions with the tumor immune microenvironment remain incompletely characterized. Methods: Transcriptomic, somatic mutation, and clinical data from TCGA-ESCC (n = 95) were analyzed using a predefined hypothesis-driven gene panel comprising five ICP genes (PDCD1, CD274, CTLA-4, HAVCR2, LAG-3) and two EMT markers (TWIST1, MMP13). Immune cell infiltration was estimated using multiple computational deconvolution algorithms. Tumor mutational burden (TMB), ESTIMATE, and TIDE scores were assessed as exploratory immune-related metrics. Findings were validated in an independent microarray cohort (GSE53624). Results: ICP and EMT genes formed distinct yet partially overlapping expression modules. HAVCR2 demonstrated the strongest and most consistent association with EMT-related signatures across datasets. Elevated expression of most ICP genes and MMP13 was associated with poorer overall survival, whereas TWIST1 exhibited dataset-dependent prognostic behavior. ICP-high tumors were characterized by features of an immunologically active yet regulatory-enriched microenvironment, while EMT-related genes were linked to fibroblast- and stroma-dominant profiles. Advanced-stage tumors displayed concurrent immune activation and immune evasion signals. TMB was low overall and tended to decreased across stages, with no significant prognostic association. Conclusion: These findings delineate context-dependent transcriptional interactions between ICP and EMT pathways in ESCC and highlight the complexity of the tumor immune microenvironment beyond single-parameter biomarkers such as TMB. All associations are exploratory and hypothesis-generating, requiring mechanistic and prospective validation prior to translational application.
- Open Access
- 23 July 2024
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 178, 117161
Potential applications of macrophages in cancer immunotherapy
- 23 July 2024
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 178, 117161
Open AccessPotential applications of macrophages in cancer immunotherapy
- Open Access
- 18 April 2024
- Published by Springer Nature in BMC Public Health
- Vol. 24 (1) , 1-16
Prevalence of tobacco use among cancer patients in Iran: a systematic review and meta-analysis
Background: The prevalence of tobacco use among various cancer types in Iran remains a significant concern, necessitating a comprehensive analysis to understand the extent and patterns of consumption. This study aimed to systematically review and analyze existing literature to delineate the prevalence of tobacco use across different cancer types in Iran, thereby providing a robust basis for future interventions and policy formulations. Methods: Adhering to the PRISMA guidelines, we conducted a systematic review and meta-analysis of literature available in PubMed and Scopus databases. The initial search identified 351 records, out of which 44 studies were selected based on their relevance and design. These studies spanned various time frames, starting from the 2001s up until 2022, and encompassed diverse geographical locations and cancer types in Iran. To avoid bias and potential data overlap, we opted to incorporate a single comprehensive study from the Golestan Cohort, encompassing all data, while excluding 10 other studies. Our final analysis incorporated data from 34 studies, which accounted for 15,425 patients and 5,890 reported smokers. Statistical analyses were performed to calculate the overall proportion of tobacco consumption and to conduct subgroup analyses based on different variables such as cancer types, gender, geographical locations, and types of tobacco used. Results: The analysis revealed a substantial prevalence of tobacco use among cancer patients in Iran, with an overall consumption rate of 43%. This rate varied significantly, ranging from 10 to 88% across individual studies. Subgroup analyses further highlighted disparities in tobacco consumption rates across different demographics, geographic areas, and cancer types. Notably, the ‘ever’ smokers category exhibited the highest prevalence of tobacco use. The study also identified a worrying trend of high cigarette smoking rates, along with variable consumption patterns of other forms of tobacco, including waterpipe, ‘Naas’, and ‘Pipe’. Conclusions: This systematic review and meta-analysis underscores a significant association between tobacco consumption and various cancer types in Iran, with a prevalence rate among cancer patients being three times higher than the average Iranian population. The findings indicate substantial heterogeneity in tobacco use patterns, emphasizing the need for targeted interventions to address this pressing health issue. The study serves as a critical resource for shaping future policies and strategies aimed at curbing tobacco use and mitigating its adverse effects on cancer prevalence in Iran.
- 18 April 2024
- Published by Springer Nature in BMC Public Health
- Vol. 24 (1) , 1-16
Open AccessPrevalence of tobacco use among cancer patients in Iran: a systematic review and meta-analysis
Background: The prevalence of tobacco use among various cancer types in Iran remains a significant concern, necessitating a comprehensive analysis to understand the extent and patterns of consumption. This study aimed to systematically review and analyze existing literature to delineate the prevalence of tobacco use across different cancer types in Iran, thereby providing a robust basis for future interventions and policy formulations. Methods: Adhering to the PRISMA guidelines, we conducted a systematic review and meta-analysis of literature available in PubMed and Scopus databases. The initial search identified 351 records, out of which 44 studies were selected based on their relevance and design. These studies spanned various time frames, starting from the 2001s up until 2022, and encompassed diverse geographical locations and cancer types in Iran. To avoid bias and potential data overlap, we opted to incorporate a single comprehensive study from the Golestan Cohort, encompassing all data, while excluding 10 other studies. Our final analysis incorporated data from 34 studies, which accounted for 15,425 patients and 5,890 reported smokers. Statistical analyses were performed to calculate the overall proportion of tobacco consumption and to conduct subgroup analyses based on different variables such as cancer types, gender, geographical locations, and types of tobacco used. Results: The analysis revealed a substantial prevalence of tobacco use among cancer patients in Iran, with an overall consumption rate of 43%. This rate varied significantly, ranging from 10 to 88% across individual studies. Subgroup analyses further highlighted disparities in tobacco consumption rates across different demographics, geographic areas, and cancer types. Notably, the ‘ever’ smokers category exhibited the highest prevalence of tobacco use. The study also identified a worrying trend of high cigarette smoking rates, along with variable consumption patterns of other forms of tobacco, including waterpipe, ‘Naas’, and ‘Pipe’. Conclusions: This systematic review and meta-analysis underscores a significant association between tobacco consumption and various cancer types in Iran, with a prevalence rate among cancer patients being three times higher than the average Iranian population. The findings indicate substantial heterogeneity in tobacco use patterns, emphasizing the need for targeted interventions to address this pressing health issue. The study serves as a critical resource for shaping future policies and strategies aimed at curbing tobacco use and mitigating its adverse effects on cancer prevalence in Iran.
- 20 April 2023
- Published by Elsevier in Pathology - Research and Practice
- Vol. 245, 154472
Circular RNAs as the pivotal regulators of epithelial-mesenchymal transition in gastrointestinal tumor cells
- 20 April 2023
- Published by Elsevier in Pathology - Research and Practice
- Vol. 245, 154472
Circular RNAs as the pivotal regulators of epithelial-mesenchymal transition in gastrointestinal tumor cells
- 5 October 2022
- Published by Elsevier in Molecular and Cellular Probes
- Vol. 66, 101869
The expression of long non-coding RNA LINC01389, LINC00365, RP11-138J23.1, and RP11-354K4.2 in gastric cancer and their impacts on EMT
- 5 October 2022
- Published by Elsevier in Molecular and Cellular Probes
- Vol. 66, 101869
The expression of long non-coding RNA LINC01389, LINC00365, RP11-138J23.1, and RP11-354K4.2 in gastric cancer and their impacts on EMT
- 26 April 2022
- Published by Springer Nature in Molecular Biotechnology
- Vol. 65 (3) , 350-360
Construction and Quantitative Evaluation of a Tissue-Specific Sleeping Beauty by EDL2-Specific Transposase Expression in Esophageal Squamous Carcinoma Cell Line KYSE-30
Gene delivery to esophageal tissue could provide novel treatments for diseases, such as cancer. The Sleeping Beauty (SB) transposon system, as a natural and non-viral tool, is efficient at transferring transgene into the human genome for human cell genetic engineering. The plasmid-based SB transposon can insert into chromosomes through an accurate recombinase-mediated mechanism, providing long-term expression of transgene integrated into the target cells. In this study, we aimed to investigate the activity of ED-L2 tissue-specific promoter that was engineered from the Epstein-Barr Virus (EBV) and combined with the hyperactive SB100X transposase to achieve the stable expression of T2-Onc3 transposon in esophageal squamous epithelial cells. Here we constructed an SB transposon-based plasmid system to obtain the stable expression of transposon upon introduction of a hyperactive SB transposase under the control of tissue-specific ED-L2 promoter via the lipid-based delivery method in the cultured esophageal squamous cell carcinoma cells. Among established human and mouse cell lines, the (ED-L2)-SB100X transposase was active only in human esophageal stratified squamous epithelial and differentiated keratinocytes derived from skin (KYSE-30 and HaCaT cell lines), where it revealed high promoter activity. Data offered that the 782 bp sequence of ED-L2 promoter has a key role in its activity in vitro. The (ED-L2)-SB100X transposase mediated stable integration of T2-Onc3 in KYSE-30 cells, thereby providing further evidence of the tissue specificity of ED-L2 promoter. The KYSE-30 cells modified with the SB system integrate on average 187 copies of the T2-Onc3 transposon in its genome. In aggregate, the (ED-L2)-SB100X transposase can be efficiently applied for the tissue-specific stable expression of a transgene in human KYSE-30 cells using SB transposon.
- 26 April 2022
- Published by Springer Nature in Molecular Biotechnology
- Vol. 65 (3) , 350-360
Construction and Quantitative Evaluation of a Tissue-Specific Sleeping Beauty by EDL2-Specific Transposase Expression in Esophageal Squamous Carcinoma Cell Line KYSE-30
Gene delivery to esophageal tissue could provide novel treatments for diseases, such as cancer. The Sleeping Beauty (SB) transposon system, as a natural and non-viral tool, is efficient at transferring transgene into the human genome for human cell genetic engineering. The plasmid-based SB transposon can insert into chromosomes through an accurate recombinase-mediated mechanism, providing long-term expression of transgene integrated into the target cells. In this study, we aimed to investigate the activity of ED-L2 tissue-specific promoter that was engineered from the Epstein-Barr Virus (EBV) and combined with the hyperactive SB100X transposase to achieve the stable expression of T2-Onc3 transposon in esophageal squamous epithelial cells. Here we constructed an SB transposon-based plasmid system to obtain the stable expression of transposon upon introduction of a hyperactive SB transposase under the control of tissue-specific ED-L2 promoter via the lipid-based delivery method in the cultured esophageal squamous cell carcinoma cells. Among established human and mouse cell lines, the (ED-L2)-SB100X transposase was active only in human esophageal stratified squamous epithelial and differentiated keratinocytes derived from skin (KYSE-30 and HaCaT cell lines), where it revealed high promoter activity. Data offered that the 782 bp sequence of ED-L2 promoter has a key role in its activity in vitro. The (ED-L2)-SB100X transposase mediated stable integration of T2-Onc3 in KYSE-30 cells, thereby providing further evidence of the tissue specificity of ED-L2 promoter. The KYSE-30 cells modified with the SB system integrate on average 187 copies of the T2-Onc3 transposon in its genome. In aggregate, the (ED-L2)-SB100X transposase can be efficiently applied for the tissue-specific stable expression of a transgene in human KYSE-30 cells using SB transposon.
- 1 September 2021
- Published by Elsevier in Experimental Cell Research
- Vol. 406 (2) , 112757
Genetically engineered mouse models of esophageal cancer
- 1 September 2021
- Published by Elsevier in Experimental Cell Research
- Vol. 406 (2) , 112757
Genetically engineered mouse models of esophageal cancer